Recipharm has partnered with Hadasit Medical Research Services and Development to offer combined clinical, biological and chemical services.
Located in Israel, Hadasit, a wholly owned subsidiary of Hadassah Medical Organization (HMO), offers a variety of research, development and consulting services to customers, primarily in the Middle East.
With its access to HMO's clinicians and researchers, the company provides clinical-oriented R&D services that can assist customers from the point of early preclinical development up to regulatory approval, saving time and money.
Recipharm’s facility in Israel has partnered with the firm as part of its growth plans in the market and to enable a more seamless customer experience as pharmaceutical products progress through clinical phases.
“Developing a drug involves chemical, biological and clinical expertise. Our partnership with Hadasit means we can offer these services more efficiently and manage projects seamlessly from development to clinic,” Dr. Sylvia Kachalsky, Site Manager at Recipharm in Israel, said. “The partnership will support business growth in Israel, giving Recipharm access to the majority of the clinical trials taking place in the country. While the field of chemistry services is relatively new to this market, the growth potential is substantial, with more than 800 biotech companies in Israel and the number and size of these companies continuing to grow.”
Recipharm established in Israel in 2015 and since then the business has grown to serve more than 50 customers, primarily in Israel and the United States.
Hadasit brings a specialist services to the partnership, including in vitro analysis in various models, access to and analysis of human samples, in vivo models for multiple medical conditions, input regarding medical indications and the conducting of clinical trials at all phases.